The therapeutic monoclonal antibody market has experienced significant growth since the commercialization of the first product in 1986. As of November 10, 2014, 47 monoclonal antibody products have been approved in the US and Europe for treating various diseases, with an estimated 70 products on the market by 2020, generating nearly $125 billion in worldwide sales. The market's growth is driven by advancements in understanding diseases at a molecular level, efficient production platforms, and the increasing demand from an aging global population and rising living standards. The approval rate of new products has increased, and the market is expected to continue growing at a CAGR of 8% or more. Factors contributing to this growth include the rapid development of new targets, the expansion of the pharmaceutical market, and the increasing use of monoclonal antibodies in cost-sensitive indications. The introduction of biosimilars is also expected to modestly accelerate sales growth.The therapeutic monoclonal antibody market has experienced significant growth since the commercialization of the first product in 1986. As of November 10, 2014, 47 monoclonal antibody products have been approved in the US and Europe for treating various diseases, with an estimated 70 products on the market by 2020, generating nearly $125 billion in worldwide sales. The market's growth is driven by advancements in understanding diseases at a molecular level, efficient production platforms, and the increasing demand from an aging global population and rising living standards. The approval rate of new products has increased, and the market is expected to continue growing at a CAGR of 8% or more. Factors contributing to this growth include the rapid development of new targets, the expansion of the pharmaceutical market, and the increasing use of monoclonal antibodies in cost-sensitive indications. The introduction of biosimilars is also expected to modestly accelerate sales growth.